Global New Chemical Entities (NCE) Market Growth (Status and Outlook) 2025-2031

The global New Chemical Entities (NCE) market size is predicted to grow from US$ 4435 million in 2025 to US$ 8595 million in 2031; it is expected to grow at a CAGR of 11.7% from 2025 to 2031.

During the drug discovery process, new compounds or active moieties (molecules or ions responsible for physiological or pharmacological action) can arise that have not previously been FDA-approved. These compounds are called New Chemical Entities (NCE) as they have not previously been used, and they can help bring about cures and therapies for incurable diseases such as cancer due to the novelty of the drug and or compound.In the existing market, there are already companies providing CDMO services for new chemical entities, and there are also companies providing new chemical entity discovery services, which can then be handed over to other companies for drug development.

United States market for New Chemical Entities (NCE) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for New Chemical Entities (NCE) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for New Chemical Entities (NCE) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key New Chemical Entities (NCE) players cover KATSURA CHEMICAL CO., LTD, NMS Group (Accelera Srl), Adragos Pharma, Syngene, Regis Custom API, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “New Chemical Entities (NCE) Industry Forecast” looks at past sales and reviews total world New Chemical Entities (NCE) sales in 2024, providing a comprehensive analysis by region and market sector of projected New Chemical Entities (NCE) sales for 2025 through 2031. With New Chemical Entities (NCE) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world New Chemical Entities (NCE) industry.

This Insight Report provides a comprehensive analysis of the global New Chemical Entities (NCE) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on New Chemical Entities (NCE) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global New Chemical Entities (NCE) market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for New Chemical Entities (NCE) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global New Chemical Entities (NCE).

This report presents a comprehensive overview, market shares, and growth opportunities of New Chemical Entities (NCE) market by product type, application, key players and key regions and countries.

Segmentation by Type:
NCE Discovery
Drug Formulation Development
Large-scale Manufacturing

Segmentation by Application:
Tumors
Cardiovascular Diseases
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
KATSURA CHEMICAL CO., LTD
NMS Group (Accelera Srl)
Adragos Pharma
Syngene
Regis Custom API
Bachem
Suven Pharma
Aspen API
MedPharm
Intertek
Neuland Laboratories
Piramal Pharma Solutions
Sai Life Sciences
Chempro Pharma
LG Chem
Sofpromed
Aurigene Pharmaceutical Services Ltd.
Aragen Life Sciences Ltd
WuXi AppTec
PharmaBlock Sciences Nanjing Inc

Please note: The report will take approximately 2 business days to prepare and deliver.